Clin2
NCT07655362Possibly a fitNot yet recruiting

Baxdrostat for heart muscle thickening

Cardiac Remodeling

Treatments studied

Part of Heart & circulation clinical trials.

This trial tests if baxdrostat can improve heart muscle structure in people with high blood pressure and a thickened heart wall. You may qualify if you have hypertension and evidence of left ventricular hypertrophy.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
286 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 or older and willing to sign a consent form.
  • You have high blood pressure (systolic between 140 and 170 mmHg).
  • You have a thickened heart muscle (left ventricular hypertrophy) seen on an echocardiogram or MRI within the past year.
  • You have at least one additional risk factor, such as type 2 diabetes, reduced kidney function, or a history of heart failure with preserved ejection fraction.
  • You are not pregnant, breastfeeding, or planning to become pregnant, and if applicable, you agree to use effective birth control.
  • You do not have certain heart conditions, kidney failure, or recent heart events.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07686120Not yet recruiting· Phase 3
Study of baxdrostat for Chinese adults with hard-to-treat high blood pressure

This trial is testing if a new medication called baxdrostat can help lower blood pressure in people who are already taking two or more blood pressure medications but still have uncontrolled high blood pressure. It is for Chinese adults only and will compare the study drug to a placebo (inactive pill).

NCT06742723Recruiting· Phase 3
Study of baxdrostat and dapagliflozin for kidney disease and high blood pressure

This trial tests if combining baxdrostat with dapagliflozin helps protect kidney function and reduce heart risks in people with chronic kidney disease and high blood pressure. It's for adults who are already taking standard blood pressure medications.

Fairhope, Alabama
NCT06677060Recruiting· Phase 3
Study of baxdrostat plus dapagliflozin for heart risk in type 2 diabetes

This study tests whether a new drug called baxdrostat, when added to the diabetes medicine dapagliflozin (Farxiga), can prevent heart failure and heart-related death in people with type 2 diabetes, high blood pressure, and existing heart or blood vessel disease. You may be able to join if you have type 2 diabetes, heart or blood vessel disease, high blood pressure, and at least one extra risk factor for heart failure.

Birmingham, Alabama
NCT07007793Recruiting· Phase 3
Study of baxdrostat for primary aldosteronism

This trial tests a new drug called baxdrostat for people with primary aldosteronism, a condition where the adrenal glands make too much aldosterone hormone, often causing high blood pressure. The goal is to see if baxdrostat helps control blood pressure and is safe.

Los Angeles, California
NCT07222917Recruiting· Phase 2
Dapagliflozin with baxdrostat for kidney disease and high blood pressure

This trial tests if adding dapagliflozin to baxdrostat (a new blood pressure drug) reduces protein in urine better than baxdrostat alone in people with chronic kidney disease and high blood pressure. It aims to find a more effective way to protect kidney health.

Surprise, Arizona
NCT05569382Recruiting· Phase 4
Testing bisoprolol and verapamil in hypertrophic heart disease

This study tests whether two common heart medicines, bisoprolol and verapamil, improve symptoms in adults with non-obstructive hypertrophic cardiomyopathy. It may help you and your care team understand which medicine works better for symptom control and heart function.

Aarhus N

Hear when a new Cardiac Remodeling trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.